杜洛西丁治疗抑郁症的治疗参考范围修订:系统性审查和元分析
F Amann1,2, M Kochtyrew3, G Zernig3,4,2
1Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Neuroscience applied
|July 14, 2025
概括
这项研究表明,杜洛西丁 (20-120 ng/mL) 的新疗法范围是为了优化抗抑郁药的效果. 建议对个性化duloxetine剂量进行治疗药物监测,特别是在初始处方时.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 神经科学是一个神经科学.
背景情况:
- 杜洛西丁的治疗度参考范围,一种血清素和上腺素的再吸收抑制剂,尚未得到很好的确立.
- 现有的杜洛西丁治疗药物监测指南提供了初步范围.
- 需要进行系统的调查,以确定抗抑郁药效应的最佳杜洛丁度.
研究的目的:
- 为了确定杜洛西抗抑郁作用的最佳目标度.
- 为了确定影响杜洛丁血度的因素.
- 建议对杜洛丁进行修订的治疗参考范围.
主要方法:
- 对杜洛丁血度研究的系统审查和元分析.
- 对报告杜洛丁度与临床作用,不良反应,药理动力学和受体占用相关的文章的分析.
- 包括11项用于定性综合的研究和7项用于定量分析的研究.
主要成果:
- 三项研究表明,杜洛丁血度与抗抑郁药作用之间存在正相关性.
- 作为不良事件的易怒/焦虑被发现是依赖于度的.
- 最佳的血清素载体占用率 (80%) 达到10-15 ng/mL以上,而50%的北上腺素载体占用率发生在58 ng/mL以上.
结论:
- 建议使用20-120 ng/mL的治疗参考范围,以获得杜洛西的最佳抗抑郁作用.
- 由于患者对杜洛西丁度的反应不同,因此需要个性化剂量.
- 建议对duloxetine进行治疗药物监测以进行剂量定位,同时考虑吸烟和同时服用药物等因素.
相关概念视频
01:27Depressive Disorders: MDD and Dysthymia
222
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
222
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
588
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
588
01:25Antidepressant Drugs: Overview
777
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
777
01:23Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
01:18Depression: Overview
354
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
354
01:21G-protein Coupled Receptors
121.5K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
121.5K